Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

RSS icon

Both Dems, Repubs misinform constituents on healthcare policy

Members of both parties have received and answered plenty of letters from their constituents about the Affordable Care Act (ACA) and other aspects of healthcare policy. According to a fact check from ProPublica, neither side can claim it has always been truthful to the people it represents. 

Thumbnail

5 changes made in revised ACA replacement plan

Ahead of a planned March 23 vote on the American Health Care Act (AHCA), House Republican leaders released a new version of the replacement plan for the Affordable Care Act (ACA) with several big changes aimed at bolstering support for the legislation within their own party.

ACA replacement set for vote in House on March 23

The Republican-sponsored replacement for the Affordable Care Act (ACA), the American Health Care Act (AHCA), will get a vote in the full U.S. House on March 23, despite doubts that it has enough votes to pass.

MGMA to CMS: Where are the MIPS eligibility notifications?

The Medical Group Management Association (MGMA) has asked newly confirmed CMS Administrator Seema Verma to quickly release overdue eligibility information for the Merit-based Incentive Payment System (MIPS), one of two new payment tracks implemented as part of the Medicare Access and CHIP Reauthorization Act (MACRA). 

Thumbnail

Durbin: No Senate Dems will vote for AHCA, but open to discussion on drug prices

It’s the job of Sen. Dick Durbin, D-Illinois, as the Senate minority whip to know where every member of his caucus stands on major pieces of legislation. When it comes to the American Health Care Act (AHCA), the Republican-sponsored plan to repeal and replace the Affordable Care Act (ACA), he said to HealthExec “no” Democrats in the chamber would support the bill as-is.

Thumbnail

Device, drug makers would pay $1 billion extra to FDA under Trump budget

Included in President Donald Trump’s budget proposal for fiscal year 2018 is a big increase in what the medical device and pharmaceutical industries would pay the Food and Drug Administration (FDA) to cover the costs of reviewing their products.

Thumbnail

5 things to know on deregulation, Medicaid from HHS Secretary's CNN event

HHS Secretary Tom Price, MD, weighed in on a number of healthcare issues during a March 15 CNN town hall-style event, focusing mainly on defending the Republican-sponsored replacement for the Affordable Care Act (ACA).

Thumbnail

ACA exchange enrollment falls short of projections for 2017

Some 12.2 million people purchased health insurance through the Affordable Care Act (ACA) exchanges in the last open enrollment period, half a million fewer than in the 2016 and well below the 13.8 million projected by HHS under the Obama administration.

Displaying 2049 - 2056 of 2772

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup